Android app Apple app link

Teva to collaborate with Fosun Pharma for TEV-56278

By Yahoo! Finance   |   3 weeks ago
Teva to collaborate with Fosun Pharma for TEV-56278

Teva Pharmaceutical partners with Fosun Pharma to develop TEV-56278, an anti-PD1-IL2 therapy using ATTENUKINE technology. The collaboration aims to advance cancer treatment globally with low toxicity. Fosun Pharma will have exclusive rights in certain regions.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.